Abstract:Shuwei Gong, 1, &ast Shuang Lang, 2, &ast Yan Wang, 3, &ast Xiongfeng Li, 1, &ast Aixian Tian, 3 Jianxiong Ma, 3 Xinlong Ma 3 1 Department of Orthopedics, Huzhou Central Hospital, Zhejiang University Huzhou Hospital, Huzhou, Zhejiang, 313000, People's Republic of China; 2 Department of Traditional Chinese Medicine, Huzhou Central Hospital, Zhejiang University Huzhou Hospital, Huzhou, Zhejiang, 313000, People's Republic of China; 3 Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering, Orthopedic Research Institute, Tianjin Hospital, Tianjin, 300050, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jianxiong Ma; Xinlong Ma, Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering, Orthopedic Research Institute, Tianjin Hospital, 155 Munan Road, Heping District, Tianjin, 300050, People's Republic of China, Email ; Background: It is well-established that osteoclast activity is significantly influenced by fluctuations in intracellular pH. Consequently, a pH-sensitive gated nano-drug delivery system represents a promising therapeutic approach to mitigate osteoclast overactivity. Our prior research indicated that naringin, a natural flavonoid, effectively mitigates osteoclast activity. However, naringin showed low oral availability and short half-life, which hinders its clinical application. We developed a drug delivery system wherein chitosan, as gatekeepers, coats mesoporous silica nanoparticles loaded with naringin (CS@MSNs-Naringin). However, the inhibitory effects of CS@MSNs-Naringin on osteoclasts and the underlying mechanisms remain unclear, warranting further research. Methods: First, we synthesized CS@MSNs-Naringin and conducted a comprehensive characterization. We also measured drug release rates in a pH gradient solution and verified its biosafety. Subsequently, we investigated the impact of CS@MSNs-Naringin on osteoclasts induced by bone marrow-derived macrophages, focusing on differentiation and bone resorption activity while exploring potential mechanisms. Finally, we established a rat model of bilateral critical-sized calvarial bone defects, in which CS@MSNs-Naringin was dispersed in GelMA hydrogel to achieve in situ drug delivery. We observed the ability of CS@MSNs-Naringin to promote bone regeneration and inhibit osteoclast activity in vivo. Results: CS@MSNs-Naringin exhibited high uniformity and dispersity, low cytotoxicity (concentration≤ 120 μg/mL), and significant pH sensitivity. In vitro, compared to Naringin and MSNs-Naringin, CS@MSNs-Naringin more effectively inhibited the formation and bone resorption activity of osteoclasts. This effect was accompanied by decreased phosphorylation of key factors in the NF-κB and MAPK signaling pathways, increased apoptosis levels, and a subsequent reduction in the production of osteoclast-specific genes and proteins. In vivo, CS@MSNs-Naringin outperformed Naringin and MSNs-Naringin, promoting new bone formation while inhibiting osteoclast activity to a greater extent. Conclusion: Our research suggested that CS@MSNs-Naringin exhibited the strikingly ability to anti-osteoclasts in vitro and in vivo, moreover promoted bone regeneration in the calvarial bone defect. Keywords: pH-sensitive gated nano-drug delivery system, mesoporous silica nanoparticles, naringin, chitosan, osteoclast Graphical Osteoclasts are giant multinucleated cells (nucleus ≥3) formed through the fusion of mononuclear cells that play a pivotal role in bone resorption. 1,2 Single osteoclasts live for a long time, at least 12 weeks, and about two-thirds of the cells can live up to 24 week. 3 The delicate balance between osteoblast-induced bone formation and osteoclast-induced bone resorption is vital for maintaining bone homeostasis. 1 Excessive bone resorption can disrupt the bone microstructure, leading to delayed healing of bone defects, fractures, and conditions such as osteoporosis, osteoclastoma, and Paget's disease, among others. 4 Notably, the biology of osteoclasts is closely tied to proton activity. The energy metabolism of osteoclasts is fascinating and complex. In brief, osteoclast differentiation and bone resorption require metabolic reprogramming, which requires a lot of energy and is prone to lactic acid accumulation. 5,6 Besides, they dissolve bone matrix by secreting H + into the sealing lacuna through vacuolar H + -ATPase (V-ATPase) during bone resorption. In turn, some of the released H + is then reabsorbed into the cell from the sealing lacu -Abstract Truncated-

Bioactive silica nanoparticles target autophagy, NF-κB, and MAPK pathways to inhibit osteoclastogenesis

Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis

Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles

Silica nanocarrier-mediated intracellular delivery of rapamycin promotes autophagy-mediated M2 macrophage polarization to regulate bone regeneration

Accelerated Bone Regeneration by Gold-Nanoparticle-Loaded Mesoporous Silica through Stimulating Immunomodulation

Smart Nanosacrificial Layer on the Bone Surface Prevents Osteoporosis through Acid–Base Neutralization Regulated Biocascade Effects

Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo

Carboxylated Gold Nanoparticles Inhibit Bone Erosion by Disturbing the Acidification of an Osteoclast Absorption Microenvironment.

The role of orthosilicic acid-induced autophagy on promoting differentiation and mineralization of osteoblastic cells

Injectable mesoporous bioactive nanoparticles regenerate bone tissue under osteoporosis conditions

Osteoprotegerin Inhibit Osteoclast Differentiation and Bone Resorption by Enhancing Autophagy Via AMPK/mTOR/p70S6K Signaling Pathway in Vitro

pH-Responsive Mesoporous Silica Nanoparticles Loaded with Naringin for Targeted Osteoclast Inhibition and Bone Regeneration

Attenuating osteoarthritis by a high efficient anti-bone resorption injectable pH-responsive bisphosphonate-conjugated nano-apatite system

Osteoimmunomodulatory Nanoparticles for Bone Regeneration

Salicylic Acid-Based Nanomedicine with Self-Immunomodulatoryactivity Facilitates Microrna Therapy for Metabolic Skeletal Disorders

Bone Formation Promoted by Bone Morphogenetic Protein-2 Plasmid-Loaded Porous Silica Nanoparticles with the Involvement of Autophagy

The Stimulatory Effect of Silica Nanoparticles on Osteogenic Differentiation of Human Mesenchymal Stem Cells

Breaking Osteoclast‐Acid Vicious Cycle to Rescue Osteoporosis via an Acid Responsive Organic Framework‐Based Neutralizing and Gene Editing Platform

Pentapeptide-decorated Silica Nanoparticles Loading Salmon Calcitonin for in Vivo Osteoporosis Treatment with Sustained Hypocalcemic Effect

A Bone Targeting Nanoparticle Loaded Ogp to Restore Bone Homeostasis for Osteoporosis Therapy

Nanoengineering multifunctional extracellular vesicles availably mitigate bone loss in osteoporosis through binding to RANKL and rebalancing the Treg/Th17 cells